Massachusetts Institute of Technology

Johns Hopkins University

University of Massachusetts

William Mark Saltzman

Bernhard A Sabel

Andrew Freese

Alex Bruce MacDonald

Judith A Whittum-Hudson

Matthew J During

A genus specific chlamydia oral or injectable vaccine is provided which comprises an anti-idiotype antibody capable of producing in an animal an anti-idiotypic antibody or Fab fragment thereof enclosed in microspheres formed of a pharmacologically acceptable polymer is capable of producing in an animal an anti-anti-idiotypic immune response (serum antibody, secretory antibody or T-cell responsee) which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The oral or injectable vaccine is produced from an idiotypic antibody to GLXA which, in turn, is utilized to produce the anti-idiotypic antibody.

Oral vaccine comprising anti-idiotypic antibody to chlamydia glycolipid

Disclosed is a polymeric drug delivery system for delivery of any substance to the central nervous system. The delivery system is preferably implanted in the central nervous system for delivery of the drug directly to the central nervous system. These implantable devices can be used, for example, to achieve continuous delivery of dopamine, which cannot pass the blood brain barrier, directly into the brain for an extended time period. The implantable devices display controlled, 'zero-order' release kinetics, a life time of a minimum of several weeks or months even when the devices contain water soluble, low molecular weight compounds, biocompatibility, and relative non-invasiveness. The polymeric devices are applicable in the treatment of a variety of central nervous system disorders including Parkinson's disease, Alzheimer's dementia, Huntington's disease, epilepsy, trauma, stroke, depression and other types of neurological and psychiatric illnesses.

Polymeric device for controlled drug delivery to the CNS

Growing community of inventors

Baltimore, MD, United States of America

William Mark Saltzman